UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB/A
AMENDMENT NO. 1 TO FORM 10-KSB
X ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year ended June 30, 1996
Commission file number 0-23280
NEUROBIOLOGICAL TECHNOLOGIES, INC.
(Name of small business issuer as specified in its charter)
Delaware 94-3049219
(State of incorporation) (IRS Employer Identification No.)
1387 Marina Way South
Richmond, California 94804
(Address of principal executive offices)
(510) 215-8000
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b)
of the Act: None Securities registered
pursuant to Section 12(g) of the Act:
Common stock $.001 Par Value
(Title of class)
Check whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days:
Yes X No
Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation SB contained herein, and no disclosure will be contained, to
the best of the Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. X
Registrant's revenues for its most recent fiscal year were $506,242.
As of June 30, 1996, the Registrant had 6,512,485 shares of Common Stock,
$.001 par value, outstanding, and the aggregate market value of the shares held
by non-affiliates on that date was $43,145,213 based upon the last sale price of
the Issuer's Common Stock reported on the Nasdaq National Market.
<PAGE>
PART III
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K
(C) EXHIBITS
<TABLE>
The following exhibits are incorporated by reference or filed as part of
this amendment to report.
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
- ---------------------------------------------------------------------------------------------------------------------------
<S> <C>
10.16*** Employment Agreement between the Registrant and Michael S. Ostrach dated June 22, 1996.
<FN>
***This exhibit is a management contract or compensatory plan or arrangement.
</FN>
</TABLE>
<PAGE>
Pursuant to the requirements of the Securities Exchange Act of 1934, this
Amendment to Report has been signed below by the following persons on behalf of
the Registrant and in the capacities and on the dates indicated.
Dated: October 1, 1996
Neurobiological Technologies, Inc.
/s/ Jeffrey S. Price
---------------------
President, Chief Executive Officer
AGREEMENT
THIS AGREEMENT is entered into as of June 22, 1996, by and between
MICHAEL OSTRACH (the "Employee") and NEUROBIOLOGICAL TECHNOLOGIES, INC., a
Delaware corporation (the "Company").
1. Term of Agreement.
This Agreement shall remain in effect from the date hereof until the
date when the Company has met all of its obligations under this Agreement.
2. Entitlement to Severance Pay and Benefits.
The Employee shall be entitled to receive the severance pay described
in Section 4 (the "Severance Pay") from the Company if (a) his employment with
the Company terminates for any reason and (b) he executes a waiver of claims and
general release in favor of the Company; provided that Employee shall not be
required to waive or release the Company from obligations, if any, which it may
have to indemnify Employee. The Company shall execute a waiver of claims and
general release in favor of the Employee. The Company shall not be required to
give advance notice of termination if it elects to terminate the Employee's
employment.
3. Definition of Continuation Period.
For all purposes under this Agreement, "Continuation Period" shall mean
the period commencing on the date when the termination of the Employee's
employment is effective and ending on the earliest of:
(a) The date 12 months after the date when the employment
termination was effective;
(b) The date when the Employee commences full-time employment
with another employer; or
(c) The date of the Employee's death.
4. Amount of Severance Pay.
During the Continuation Period, the Company shall pay the Employee
Severance Pay at an annual rate equal to his base compensation at the annual
rate in effect on the date when the termination of his employment with the
Company is effective. Such amount shall be paid at periodic intervals in
accordance with the Company's standard payroll procedures, except that the
Severance Pay for the first three months of the Continuation
-1-
<PAGE>
Period shall be paid in a lump sum within five working days after the Employee's
employment with the Company terminated. Such lump sum shall not be subject to
repayment, even if the Employee commences full-time employment with another
employer within three months after his employment with the Company terminates.
5. Stock Options and Group Insurance.
(a) Stock Options. If the Employee's employment with the Company
terminates for any reason, all of his options to purchase shares of the
Company's stock shall immediately become exercisable in full. Such options shall
remain exercisable for 12 months following the employment termination date,
notwithstanding any contrary provisions in the applicable stock option
agreements. The Employee represents that he has consulted or will consult a tax
adviser regarding the impact of this Subsection (a) on the tax treatment of
incentive stock options.
(b) Group Insurance. During the Continuation Period, the Employee (and,
where applicable, his dependents) shall be entitled to continue participation in
the group insurance plans maintained by the Company, including life, disability
and health insurance programs, as if he were still an employee of the Company.
Where applicable, the Employee's salary for purposes of such plans shall be
deemed to be equal to his base compensation at the rate in effect on the date
when the termination of the Employee's employment with the Company is effective.
To the extent that the Company finds it impossible to cover the Employee under
its group insurance policies during the Continuation Period, the Company shall
provide the Employee with individual policies which offer at least the same
level of coverage and which impose not more than the same costs on him. Any
group health continuation coverage that the Company is required to offer under
the Consolidated Omnibus Budget Reconciliation Act of 1986 shall commence when
coverage under this Subsection (b) terminates.
6. Consulting Services.
During the Continuation Period, Employee agrees to provide consulting
services to the Company, as requested by the Company, up to a maximum of
one-half of one full work day per month.
7. Successors.
(a) Company's Successors. The Company shall require any successor
(whether direct or indirect and whether by purchase, lease, merger,
consolidation, liquidation or otherwise) to all or substantially all of the
Company's business and/or assets, by an agreement in substance and form
satisfactory to the Employee, to assume this Agreement and to agree expressly to
perform this
-2-
<PAGE>
Agreement in the same manner and to the same extent as the Company would be
required to perform it in the absence of a succession. For all purposes under
this Agreement, the term "Company" shall include any successor to the Company's
business and/or assets which executes and delivers the assumption agreement
described in this Subsection (a) or which becomes bound by this Agreement by
operation of law.
(b) Employee's Successors. This Agreement and all rights of the
Employee hereunder shall inure to the benefit of, and be enforceable by, the
Employee's personal or legal representa- tives, executors, administrators,
successors, heirs, distributees, devisees and legatees.
8. Miscellaneous Provisions.
(a) Notice. Notices and all other communications contemplated by this
Agreement shall be in writing and shall be deemed to have been duly given when
personally delivered or when mailed by U.S. registered or certified mail, return
receipt requested and postage prepaid. In the case of the Employee, mailed
notices shall be addressed to him at the home address which he most recently
communicated to the Company in writing. In the case of the Company, mailed
notices shall be addressed to its corporate headquarters, and all notices shall
be directed to the attention of its Chief Executive Officer.
(b) Waiver. No provision of this Agreement shall be modified, waived or
discharged unless the modification, waiver or discharge is agreed to in writing
and signed by the Employee and by an authorized officer of the Company (other
than the Employee). No waiver by either party of any breach of, or of compliance
with, any condition or provision of this Agreement by the other party shall be
considered a waiver of any other condition or provision or of the same condition
or provision at another time.
(c) Whole Agreement. No agreements, representations or understandings
(whether oral or written and whether express or implied) which are not expressly
set forth in this Agreement have been made or entered into by either party with
respect to the subject matter hereof.
(d) No Setoff; Withholding Taxes. There shall be no right of setoff or
counterclaim, with respect to any claim, debt or obligation, against payments to
the Employee under this Agreement. All payments made under this Agreement shall
be subject to reduction to reflect taxes required to be withheld by law.
(e) Choice of Law. The validity, interpretation, con- struction and
performance of this Agreement shall be governed by the laws of the State of
California.
-3-
<PAGE>
(f) Severability. The invalidity or unenforceability of any provision
or provisions of this Agreement shall not affect the validity or enforceability
of any other provision hereof, which shall remain in full force and effect.
(g) Arbitration. Any controversy or claim arising out of or relating to
this Agreement, or the breach thereof, shall be settled by arbitration in San
Francisco in accordance with the Commercial Arbitration Rules of the American
Arbitration Association. Discovery shall be permitted to the same extent as in a
proceeding under the Federal Rules of Civil Procedure, including (without
limitation) such discovery as is specifically authorized by section 1283.05 of
the California Code of Civil Procedure, without need of prior leave of the
arbitrator under section 1283.05(e) of such Code. Judgment on the award rendered
by the arbitrator may be entered in any court having jurisdiction thereof. All
fees and expenses of the arbitrator and such Association shall be paid as
determined by the arbitrator.
(h) No Assignment. The rights of any person to payments or benefits
under this Agreement shall not be made subject to option or assignment, either
by voluntary or involuntary assignment or by operation of law, including
(without limitation) bankruptcy, garnishment, attachment or other creditor's
process, and any action in violation of this Subsection (h) shall be void.
IN WITNESS WHEREOF, each of the parties has executed this Agreement, in
the case of the Company by its duly authorized officer, as of the day and year
first above written.
MICHAEL S. OSTRACH
/s/ Michael S. Ostrach
-----------------------------------
NEUROBIOLOGICAL TECHNOLOGIES, INC.
By: /s/ Jeffrey s. Price, Ph.D.
-----------------------------------
Title: President and Chief
Executive Officer
-4-
